Search

This decision aid can be used with your doctor to help you decide whether to use antibiotics when you have a flare-up (exacerbation) of your chronic obstructive pulmonary disease (COPD). 

This decision aid can be used with your doctor to help you decide whether to use antibiotics when you or your child has sinusitis (acute rhinosinusitis).

This PowerPoint presentation is designed to assist consumers deliver the educational session for Partnering with Consumers: A guide for consumers, and can be used in partnership with staff from the local health service organisation.

This Facilitator Guide is designed to assist consumers deliver the educational session for Partnering with Consumers: A guide for consumers, and can be used in partnership with staff from the local health service organisation.

This case study is one of four, designed to align with Partnering with Consumers: A guide for consumers. It focuses on the Emergency Department Consumer Advisory Group at Fiona Stanley Hospital and how consumer leadership has changed the way that services are designed, delivered and evaluated. 

This case study is one of four, designed to align with the Partnering with Consumers: A guide for consumers. It focuses on the evidence-based Eat Walk Engage program, that aims to improve outcomes for older people at risk of more serious hospital complications (such as delirium). 

This case study is one of four, designed to align with Partnering with Consumers: A guide for consumers. It highlights the strategies that South Metropolitan Health Service uses to implement the the National Safety and Quality Health Service (NSQHS) Standards with a focus on partnering with consumers at all levels of the organisation.

This case study is one of four, designed to align with Partnering with Consumers: A guide for consumers. It focuses on initiatives to strengthen person-centred care as part of the redevelopment of a multipurpose service to co-locate aged care and acute services.

This Communiqué provides an update on the first meeting of the National Sepsis Oversight Group (Oversight Group). It may be used by members to update their nominating organisations and other key stakeholders about the National Sepsis Program Extension (Program Extension).

This issue includes items on prevention, oral health, medication safety, patient engagement, COVID-19, and more. Also covered are the latest from Australian Prescriber, BMJ Quality & Safety, Pediatric Quality & Safety, Public Health Research & Practice and International Journal for Quality in Health Care.

This Communiqué provides an update on the second meeting of the National Sepsis Oversight Group (Oversight Group). It may be used by members to update their nominating organisations and other key agencies about the National Sepsis Program Extension (Program Extension).

This issue includes items on the new Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard, digital technology, remote or telehealth, nursing care, end of life care, patient perspectives, COVID-19, and more. 

Also covered are the latest from BMJ Quality & Safety, Journal for Healthcare Quality (JHQ), Health Affairs, Health Affairs Scholar and International Journal for Quality in Health Care along with the latest from the UK’s NICE and the USA’s AHRQ.

This resource accompanies the Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard. It describes what the quality statements mean for healthcare services and provides indicators to support local quality improvement activity.

This resource lists the eight quality statements in the clinical care standard that aim to ensure the safe and appropriate use of psychotropic medicines in people with cognitive disability or impairment.

The standard contains eight quality statements that describe the health care you should receive to support the correct use of psychotropic medicines. This fact sheet explains each quality statement and what it means for you.  

The Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard contains eight quality statements and seven indicators to ensure the safe and appropriate use of psychotropic medicines in people with cognitive disability or impairment and uphold their rights, dignity, health and quality of life.